News and FDA Updates for ARIAD (NASDAQ:ARIA), Avisio (OTC:AVIC), Beckman Coulter (NYSE:BEC)
A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com
On 03/03/10, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it will present at the 30th Annual Cowen Healthcare Conference being held at the Boston Marriot Copley Place in Boston, Massachusetts. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Wednesday, March 10, 2010 at 8:00 a.m. (ET).
On 03/03/10, Avisio, Inc. (OTC:AVIC) announced it has engaged Silberstein Ungar, PLLCto serve as Avisio's independent auditors.
On 03/03/10, Beckman Coulter, Inc. (NYSE:BEC), a leading developer, manufacturer, and marketer of products which simplify, automate, and innovate complex biomedical testing, announced Scott Garrett, Beckman Coulter's chairman, president and chief executive officer, will present at the Cowen Healthcare Conference on Tuesday, March 9, 2010, at 10:20 a.m. ET.
Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
Disclosure: No positions.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters´ expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company´s behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

